A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer
This study is PhaseⅠstudy to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients with metastatic pancreatic cancer as first-line treatment
Metastatic Pancreatic Cancer
DRUG: ONO-7475|DRUG: ONO-4538|DRUG: Nab-paclitaxel|DRUG: Gemcitabine
Dose-limiting toxicities (DLT), 28 days|Adverse event (AE), Up to 28 days after the last dose
Pharmacokinetics (Plasma concentration of ONO-7475), Up to Cycle16|Pharmacokinetics (Plasma concentration of ONO-4538), Through study completion, an average of 6 months|Anti-ONO-4538 antibody, Through study completion, an average of 6 months|Objective Response Rate (ORR), Through study completion, an average of 6 months|Disease Control Rate (DCR), Through study completion, an average of 6 months|Overall Survival (OS), Through study completion, an average of 1 year|Progression-Free Survival (PFS), Through study completion, an average of 6 months|Duration of Response (DOR), Through study completion, an average of 6 months|Time to Response (TTR), Through study completion, an average of 6 months|Best Overall Response (BOR), Through study completion, an average of 6 months|Percent change in the sum diameters of the target lesions, Through study completion, an average of 6 months|Maximum percent change in the sum diameters of the target lesions, Through study completion, an average of 6 months|CEA, Through study completion, an average of 6 months|CA19-9, Through study completion, an average of 6 months
This study is PhaseⅠstudy to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients with metastatic pancreatic cancer as first-line treatment